Get the Stockscreener App
26.22
1.87%
-0.52
Pacira Biosciences Inc stock is traded at $26.22, with a volume of 163.80K.
It is down -1.87% in the last 24 hours and up +4.33% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$26.74
Open:
$26.68
24h Volume:
163.80K
Relative Volume:
0.19
Market Cap:
$1.22B
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
18.08
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
+1.55%
1M Performance:
+4.33%
6M Performance:
+36.17%
1Y Performance:
-9.89%
1-Day Range:
$26.23
$27.18
1-Week Range:
$25.36
$27.42
52-Week Range:
$11.16
$29.95
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
26.25 | 1.20B | 681.75M | 70.47M | 173.19M | 1.45 |
|
HLN
Haleon Plc Adr
|
11.07 | 50.98B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
169.71 | 74.41B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.935 | 4.03M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.94 | 46.23B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.55 | 20.10B | 16.54B | -1.64B | 749.00M | -1.45 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect - ACCESS Newswire
Pacira (PCRX) BioSciences Grants Inducement Awards to New Employ - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira Expands Team: 19 New Hires Receive $1.8M in Stock Awards and Options - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Two Sigma Investments LP Purchases 45,222 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Q3 EPS Estimate for Pacira BioSciences Raised by Analyst - Defense World
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by ProShare Advisors LLC - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences’s First Quarter 2025 Misses Estimates - Orthopedics This Week
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Nuveen Asset Management LLC - Defense World
Grabar Law Office Investigates Claims on Behalf of - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out - ACCESS Newswire
Trading (PCRX) With Integrated Risk Controls - news.stocktradersdaily.com
Ameriprise Financial Inc. Acquires 194,597 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Pacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57% - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2025-05-18 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation | Press Release - Stockhouse
The Manufacturers Life Insurance Company Sells 458 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Comerica Bank - Defense World
Northern Trust Corp Buys 145,205 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - GuruFocus
Pacira (PCRX) Reports Promising Data on PCRX-201 Gene Therapy fo - GuruFocus
Pacira (PCRX) Reports Promising Data on PCRX-201 Gene Therapy for Knee Osteoarthritis | PCRX Stock News - GuruFocus
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee - The Manila Times
Pacira BioSciences Presents New Data on the Effects of - GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences - GlobeNewswire
Pacira Biosciences announces $300M share repurchase program - MSN
Non-Opioid Pain Leader Pacira BioSciences Sets Major Investor Presentations at RBC and Jefferies Conferences - Stock Titan
(PCRX) Trading Report - news.stocktradersdaily.com
Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation - PR Newswire
2025-05-13 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out | Press Release - Stockhouse
Raymond James Financial Inc. Invests $190,000 in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Tower Research Capital LLC TRC - Defense World
Needham & Company LLC Cuts Pacira BioSciences (NASDAQ:PCRX) Price Target to $30.00 - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Shareholders of Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your RightsPCRX - ACCESS Newswire
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Down on Analyst Downgrade - Defense World
Pacira BioSciences (PCRX) Stock Rating Maintained but Price Targ - GuruFocus
Levi & Korsinsky Reminds Pacira BioSciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025PCRX - ACCESS Newswire
Pacira outlines growth potential with $725M-$765M 2025 revenue target and EXPAREL expansion to 2039 - MSN
Earnings call transcript: Pacira Q1 2025 shows revenue miss, stock dips - Investing.com Australia
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates - Nasdaq
Pacira BioSciences (PCRX) Stock Rating Maintained but Price Target Lowered | PCRX Stock News - GuruFocus
Where Pacira BioSciences Stands With Analysts - Benzinga
Pacira BioSciences Q1 2025 Earnings Call Transcript - MarketBeat
Pacira Q1 Adjusted Earnings Unchanged; Revenue Rises; 2025 Sales Guidance Steady - marketscreener.com
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):